A. Pieter Kappetein1*, MD, PhD; Stuart J. Head1, MS; Hendrik Treede2, MD; Hermann Reichenspurner2, MD, PhD; Friedrich W. Mohr3, MD, PhD; Thomas Walther4, MD, PhD
1. Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Cardiovascular Surgery, University Heart Center, Hamburg, Germany; 3. Deparment of Cardiac Surgery, Heart Center,
Recently, transcatheter aortic valve replacement (TAVR) has been shown to result in similar 12-month survival as surgical aortic valve replacement (SAVR) for high-risk patients with severe aortic stenosis1. For patients deemed inoperable TAVR showed a 20% survival benefit at one year compared to medical treatment2.
The PARTNER Trial
During the focused late-breaking clinical trial session at TCT in San Francisco new data on TAVR were presented. Good news came from the PARTNER B trial which tested TAVR with the SAPIEN device (Edwards Lifesciences, Irvine, CA, USA) in inoperable patients against best medical care. Data showed that survival curves are ...